Stock Quote

RemeGen Cleared to Start US Trials of Novel ADC for HER2 Urothelial Cancer

RemeGen, a Yantai biopharma, was cleared to start a US Phase II trial of its HER2 antibody drug conjugate (ADC) in patients with HER2 positive metastatic or unresectable urothelial cancer (UC). One year ago, RemeGen reported a China Phase II trial of RC48 (disitamab vedotin) produced a 51% objective response rate in the same population. Earlier this month, RemeGen closed a $100 million funding co-led by Lilly Asia Ventures and Lake Bleu Capital. The company has filed a China NDA for its lead drug, telitacicept, a fusion protein aimed at lupus. More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.